Details for New Drug Application (NDA): 207931
✉ Email this page to a colleague
NDA 207931 describes TECHNIVIE, which is a drug marketed by Abbvie and is included in one NDA. There are six patents protecting this drug. Additional details are available on the TECHNIVIE profile page.
The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.
The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.
Summary for 207931
| Tradename: | TECHNIVIE |
| Applicant: | Abbvie |
| Ingredient: | ombitasvir; paritaprevir; ritonavir |
| Patents: | 6 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 207931
Generic Entry Date for 207931*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Jul 24, 2015 | TE: | RLD: | Yes | |||||
| Patent: | 8,420,596*PED | Patent Expiration: | Oct 10, 2031 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
| Patent: | 8,642,538 | Patent Expiration: | Sep 10, 2029 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | TREATMENT OF HCV INFECTION USING PARITAPREVIR | ||||||||
| Patent: | 8,686,026 | Patent Expiration: | Jun 9, 2031 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
